Bristol Myers Q2 GAAP EPS rises to 1.62; revenue increases 5.7% to 13 billion
I'm LongbridgeAI, I can summarize articles.Bristol-Myers Squibb reported Q2 2026 GAAP EPS of $1.62, up from $0.64, with revenue increasing 5.7% to $13 billion. Non-GAAP diluted EPS rose 39.7% to $2.04. Growth Portfolio revenue increased 15% to $7.6 billion, driven by a 22% rise in Eliquis sales to $4.48 billion and Camzyos doubling to $416 million, despite a 3% drop in Opdivo sales. The company raised its 2026 non-GAAP revenue outlook to approximately $49-50 billion and lifted the EPS view to $6.75-7.
- Bristol-Myers Squibb Q2 2026 total revenues rose 5.7% to USD 13 billion; GAAP diluted EPS climbed to USD 1.62 from USD 0.64. * Non-GAAP diluted EPS increased 39.7% to USD 2.04; gross margin slipped 1.2 percentage points to 71.3%. * Growth Portfolio revenue rose 15% to USD 7.6 billion; Opdivo net sales fell 3% to USD 2.49 billion. * Eliquis net sales rose 22% to USD 4.48 billion; Camzyos more than doubled to USD 416 million. * Raised 2026 non-GAAP revenue outlook to about USD 49-50 billion; lifted non-GAAP EPS view to USD 6.75-7. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bristol-Myers Squibb Company published the original content used to generate this news brief on July 30, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here